Together, the combined organization will offer a comprehensive portfolio of tablet compression solutions backed by expanded manufacturing capabilities.
The transaction aims to enhance operational excellence, unlock additional growth opportunities, and further strengthen Samsung Biologics' position as a leading global multi-modality CDMO.
As small-molecule pipelines grow more complex, formulation has become a decisive factor in whether promising compounds reach patients. Learn more in this eBook from Bend Bioscience and Contract Pharma.
Solvias is a global provider of CMC analytics to the pharmaceutical and biotech industry. Our expert teams combine 25 years of experience with regulatory understanding across small molecules, biologics, and cell and gene therapies. We offer comprehensive solutions from raw materials to drug substance & product to final release testing.
INCOG BioPharma is a global fill/finish CDMO providing end-to-end solutions for clinical through commercial phase sterile injectable drug products. Our facility is FDA approved, Annex 1 compliant, and uses the latest technology to provide tailored manufacturing solutions. We fill into syringes, vials, and cartridges, and offer autoinjector assembly, final packaging solutions, and in-house analytics. Our experienced team creates value for customers by decreasing manufacturing times and simplifying complex supply chains, enabling drug developers to focus on advancing their therapies with confidence.
